Last quarter (Q3 2024), Lexeo Therapeutics, Inc.'s total revenue was $―, a decrease of ― from previous quarter. In Q3, Lexeo Therapeutics, Inc.'s net income was $-29.49M. See Lexeo Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22
Total Revenue	$ ―	$ ―	$ 654.00K
Cost of Revenue	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ ―	$ 654.00K
Operating Expense	$ 55.09M	$ 68.51M	$ 61.16M
Operating Income	$ -55.09M	$ -68.51M	$ -60.51M
Net Non Operating Interest Income Expense	$ 4.41M	$ 2.66M	$ 1.23M
Other Income Expense	$ 4.00K	$ 543.00K	$ 2.00K
Pretax Income	$ -50.73M	$ -66.39M	$ -59.28M
Tax Provision	$ ―	$ ―	$ ―
Earnings From Equity Interest Net Of Tax	$ ―	$ -530.00K	$ ―
Net Income Common Stockholders	$ -50.73M	$ -66.39M	$ -59.28M
Basic EPS	$ -1.53	$ -12.40	$ -36.36
Diluted EPS	$ -1.53	$ -12.40	$ -36.36
Basic Average Shares	$ 66.07M	$ 5.35M	$ 1.63M
Diluted Average Shares	$ 66.07M	$ 5.35M	$ 1.63M
Dividend Per Share	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―
Total Expenses	$ 55.09M	$ 68.51M	$ 61.16M
Net Income From Continuing And Discontinued Operation	$ -50.73M	$ -66.39M	$ -59.28M
Normalized Income	$ -50.22M	$ -51.92M	$ ―
Interest Expense	$ ―	$ ―	$ ―
EBIT	$ -50.66M	$ -66.19M	$ ―
EBITDA	$ -49.65M	$ -64.35M	$ ―

Currency in USD

Lexeo Therapeutics, Inc. Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing